PMID- 15976989
OWN - NLM
STAT- MEDLINE
DCOM- 20060929
LR  - 20181201
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 61
IP  - 5-6
DP  - 2005 Jul
TI  - Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with 
      acid-related disorders with Helicobacter pylori infection.
PG  - 375-9
AB  - A proton pump inhibitor (PPI) plus two antibiotics (amoxicillin and either 
      clarithromycin or metronidazole) are recommended for treatment of acid-related 
      disorders with Helicobacter pylori (H. pylori) infection. The aim of this 
      pharmacogenetic study was to evaluate the efficacy of triple therapy with PPIs on 
      eradication of H. pylori infection in relation to cytochrome P450 2C19 (CYP2C19) 
      and P-glycoprotein (MDR1) gene polymorphisms. The retrospective study involved 70 
      Polish Caucasian patients with H. pylori infection, diagnosed and treated with 
      one of the two different triple therapy regimens [omeprazole, amoxicillin, and 
      clarithromycin (OAC) or pantoprazole, amoxicillin, and metronidazole (PAM)]. 
      Using genomic DNA, CYP2C19 (*2 and *3) and C3435T MDR1 alleles were determined by 
      means of polymerase chain reaction-restriction fragment length polymorphism 
      assays. A significantly higher prevalence (P<0.05) of heterozygous extensive 
      metabolizers (hetEM) with CYP2C19*1/*2 genotype (32.4% versus 8.3%) and 
      homozygous with 3435TT MDR1 genotype (38.2% versus 13.9%) was found in patients 
      cured after the first cycle of triple therapy than in patients with failure of 
      eradication after the first cycle. CYP2C19*1/*2 and 3435TT MDR1 genotypes as well 
      as PAM regimen of treatment were also predictive of successful eradication of H. 
      pylori infection after the first cycle of triple therapy at 
      univariate/multivariate logistic regression analysis. This pharmacogenetic study 
      on the influence of different CYP2C19 and C3435T MDR1 genotypes on H. pylori 
      eradication suggests that CYP2C19 and MDR1 polymorphisms may be independent 
      predictable determinants of the efficacy of triple therapy including PPI. The PAM 
      regimen of treatment seems to be more effective after the first cycle of the 
      therapy than the OAC regimen.
FAU - Gawronska-Szklarz, Barbara
AU  - Gawronska-Szklarz B
AD  - Department of Pharmacology, Pomeranian Medical University, Al. Powstancow Wlkp. 
      72, 70-111, Szczecin, Poland.
FAU - Wrzesniewska, Joanna
AU  - Wrzesniewska J
FAU - Starzynska, Teresa
AU  - Starzynska T
FAU - Pawlik, Andrzej
AU  - Pawlik A
FAU - Safranow, Krzysztof
AU  - Safranow K
FAU - Ferenc, Katarzyna
AU  - Ferenc K
FAU - Drozdzik, Marek
AU  - Drozdzik M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20050623
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Sulfoxides)
RN  - D8TST4O562 (Pantoprazole)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 1/*genetics
MH  - Adult
MH  - Aged
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aryl Hydrocarbon Hydroxylases/*genetics
MH  - Benzimidazoles/administration & dosage/*therapeutic use
MH  - Cytochrome P-450 CYP2C19
MH  - Drug Therapy, Combination
MH  - Duodenal Ulcer/*drug therapy/genetics
MH  - Female
MH  - Gastroesophageal Reflux/*drug therapy/genetics
MH  - Gene Frequency
MH  - Helicobacter Infections/*drug therapy/genetics
MH  - *Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mixed Function Oxygenases/*genetics
MH  - Omeprazole/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Pantoprazole
MH  - *Polymorphism, Genetic
MH  - Proton Pump Inhibitors
MH  - Retrospective Studies
MH  - Stomach Ulcer/*drug therapy/genetics
MH  - Sulfoxides/administration & dosage/*therapeutic use
EDAT- 2005/06/25 09:00
MHDA- 2006/09/30 09:00
CRDT- 2005/06/25 09:00
PHST- 2004/10/13 00:00 [received]
PHST- 2005/01/12 00:00 [accepted]
PHST- 2005/06/25 09:00 [pubmed]
PHST- 2006/09/30 09:00 [medline]
PHST- 2005/06/25 09:00 [entrez]
AID - 10.1007/s00228-005-0901-1 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2005 Jul;61(5-6):375-9. doi: 10.1007/s00228-005-0901-1. 
      Epub 2005 Jun 23.